Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
0R
0RV2.LSE
0R
0RV2.LSE
0RV2.LSE
News
·
Eisai increases the number of participants in Clarity AD study
Mkt Cap
N/A
Volume
N/A
Next Earnings
N/A
Chart
Earnings
News
About
Dividends
Insider
Filings
Eisai increases the number of participants in Clarity AD study
STOCKHOLM, Feb. 3, 2021 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have increased the participant target number by approximately 200 in the pivotal Phase 3 study, Clarity AD, of drug candidate lecanemab (BAN2401) for t…
finance.yahoo.com · Feb 3, 2021
Eisai increases the number of participants in Clarity AD study
STOCKHOLM, Feb. 3, 2021 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have increased the participant target number by approximately 200 in the pivotal Phase 3 study, Clarity AD, of drug candidate lecanemab (BAN2401) for t…
finance.yahoo.com · Feb 3, 2021
Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020
STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- BioArctic AB (publ) [Nasdaq Stockholm: BIOA B] announced today data on the drug candidate BAN2401 (lecanemab), which were presented by the company's partner Eisai at the Clinical Trials on Alzheimer's Disease conference (CTAD), November 4-7…
finance.yahoo.com · Nov 9, 2020
Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020
STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- BioArctic AB (publ) [Nasdaq Stockholm: BIOA B] announced today data on the drug candidate BAN2401 (lecanemab), which were presented by the company's partner Eisai at the Clinical Trials on Alzheimer's Disease conference (CTAD), November 4-7…
finance.yahoo.com · Nov 9, 2020
BioArctic's partner Eisai to present latest data on BAN2401 at CTAD conference
STOCKHOLM, Oct. 28, 2020 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company's partner Eisai will conduct four oral presentations related to the drug candidate BAN2401 (lecanemab) at the 13th Clinical Trials on Alzheimer's Disease Confe…
finance.yahoo.com · Oct 28, 2020
BioArctic's partner Eisai to present latest data on BAN2401 at CTAD conference
STOCKHOLM, Oct. 28, 2020 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company's partner Eisai will conduct four oral presentations related to the drug candidate BAN2401 (lecanemab) at the 13th Clinical Trials on Alzheimer's Disease Confe…
finance.yahoo.com · Oct 28, 2020
BioArctic winner of the Allbright Award 2020
STOCKHOLM, Oct. 15, 2020 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has been awarded the 2020 Allbright Award for its focused work with gender equality. The announcement was made on October 15 during Allbright's annual award ce…
finance.yahoo.com · Oct 15, 2020
BioArctic winner of the Allbright Award 2020
STOCKHOLM, Oct. 15, 2020 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has been awarded the 2020 Allbright Award for its focused work with gender equality. The announcement was made on October 15 during Allbright's annual award ce…
finance.yahoo.com · Oct 15, 2020
Invitation to presentation of BioArctic's Interim Report for the period January - September 2020 on October 14 at 9.30 a.m. CET
STOCKHOLM, Oct. 6, 2020 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Interim Report for the period January - September 2020 on Wednesday, October 14, 2020, at 08:00 a.m. CET. BioArctic invites to an audiocast with teleconference (in Engl…
finance.yahoo.com · Oct 6, 2020
Invitation to presentation of BioArctic's Interim Report for the period January - September 2020 on October 14 at 9.30 a.m. CET
STOCKHOLM, Oct. 6, 2020 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Interim Report for the period January - September 2020 on Wednesday, October 14, 2020, at 08:00 a.m. CET. BioArctic invites to an audiocast with teleconference (in Engl…
finance.yahoo.com · Oct 6, 2020
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
0R
0RV2.LSE
0RV2.LSE
Buy
Sell
Market
Limit
Soon
0RV2.LSE
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any 0RV2.LSE yet.
Related Tickers
Earnings
Dividends
Last · May 29
Amount
$2.00
Annual
$2.00